Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection
Open Access
- 1 December 2023
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 158 (12) , 1275-1284
Abstract
Importance: Few studies have investigated whether prophylactic salpingo-oophorectomy (PSO) for patients with previously resected breast cancer who carry pathogenic germline BRCA1 or BRCA2 variants is associated with a reduced risk of cancer-specific death.Objective: To assess the association of PSO and prophylactic mastectomy (PM) with prognosis after quadrantectomy or mastectomy as primary treatment for patients with BRCA1 or BRCA2 breast cancer.Design, Setting, and Participants: This retrospective cohort study was performed in a single-institution, tertiary referral center. Consecutive patients with invasive breast cancer treated surgically between 1972 and 2019 were recruited and followed up prospectively after they were found to carry the BRCA1 or BRCA2 gene variant. The data analysis was performed between April 2022 and July 2023.Exposure: Following breast surgery, some patients underwent PSO, PM, or both, whereas others did not.Main Outcomes and Measures: The primary study end point was overall survival as measured by the Kaplan-Meier method. Secondary end points were crude cumulative incidence of breast cancer–specific mortality, ipsilateral breast tumor recurrence (IBTR), contralateral breast cancer, ovarian cancer, and ovarian cancer–specific mortality.Results: Of 480 patients included in the cohort (median age at initial surgery, 40.0 years; IQR, 34.0-46.0 years), PSO was associated with a significantly reduced risk of death (hazard ratio [HR], 0.40; 95% CI, 0.25-0.64; P < .001). This reduction was most evident for patients carrying the BRCA1 variant (HR, 0.35; 95% CI, 0.20-0.63; P = .001), those with triple-negative disease (HR, 0.21; 95% CI, 0.09-0.46; P = .002), and those with invasive ductal carcinoma (HR, 0.51; 95% CI, 0.31-0.84; P = .008). Prophylactic salpingo-oophorectomy was not associated with risk of contralateral breast cancer or IBTR. Initial or delayed PM was associated with a reduced risk of IBTR but not with overall survival or breast cancer–specific mortality.Conclusions: The study findings suggest that PSO should be offered to all patients with BRCA1/2 breast cancer who undergo surgery with curative intent to reduce risk of death. In particular, PSO should be offered to patients with the BRCA1 variant at the time of breast surgery.Keywords
This publication has 27 references indexed in Scilit:
- Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast CancerJournal of Clinical Oncology, 2013
- Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriersBritish Journal of Cancer, 2011
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast CancerClinical Cancer Research, 2011
- Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriersBreast Cancer Research and Treatment, 2011
- Prophylactic mastectomy for the prevention of breast cancerCochrane Database of Systematic Reviews, 2010
- Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomyBreast Cancer Research and Treatment, 2010
- Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literatureBreast Cancer Research and Treatment, 2009
- Variation of Breast Cancer Risk Among BRCA1/2 CarriersJAMA, 2008
- CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancerGynecologic Oncology, 2006
- Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancerEuropean Journal of Cancer, 1995